Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?
There are several potential reasons why investors didn't cheer the companies' great news more loudly.
Full Article
Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?
Motley Fool
0 shares
2 views
You might like
Related news coverage
FTSE 100 firmly in the red; Wall Street opens on a mixed footing
FTSE 100 down 33 points COVID-19 infections fell by 65% after first dose of vaccine US stocks see mixed open 2.42pm: Mixed start..
Proactive Investors
FTSE 100 firmly in the red; COVID-19 infections fall significantly after single dose vaccines are rolled out, study shows
FTSE 100 down 41 points COVID-19 infections fell by 65% after first dose of vaccine Bitcoin drops below US$50,000 1.30pm: COVID-19..
Proactive Investors